January 7, 2025 Six Month Data from alfapump® Pivotal POSEIDON Study in Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Published in American Journal of Gastroenterology Non-regulated EN NL
January 6, 2025 Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST Regulated EN NL
December 23, 2024 Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis Regulated EN NL
December 2, 2024 Sequana Medical announces update on second tranche of convertible bridge loan Inside information, Regulated EN NL
November 27, 2024 Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical’s Direct Sodium Removal Heart Failure Program and Board Composition Update Regulated EN NL
November 20, 2024 Sequana Medical announces Extraordinary General Meeting of Shareholders on 20 December 2024 Regulated EN NL
November 18, 2024 Sequana Medical Announces Strong 24-Month Results from POSEIDON Study at AASLD The Liver Meeting® in San Diego; US PMA alfapump approval expected before end of Q1 2025 Non-regulated EN NL
November 14, 2024 Sequana Medical announces new share capital amount and new number of shares Regulated EN NL